Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.68 -1.8%	$2.18	$1.63 ▼ $4.66	$9.41M	0.81	645,528 shs	86,257 shs
BFRI Biofrontera	$0.95 -6.9%	$0.78	$0.54 ▼ $2.22	$10.34M	0.5	113,022 shs	88,362 shs
ELAB PMGC	$1.89 -1.3%	$2.20	$1.81 ▼ $546.00	$2.63M	0.17	145,716 shs	11,402 shs
IMCC IM Cannabis	$2.56 +2.0%	$2.91	$1.29 ▼ $7.12	$10.15M	2.2	60,009 shs	43,468 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	-1.75%	-21.50%	-26.64%	-41.05%	-40.21%
BFRI Biofrontera	-6.86%	-12.04%	+30.32%	+36.71%	-18.80%
ELAB PMGC	-1.31%	-9.81%	-18.04%	-20.46%	-99.62%
IMCC IM Cannabis	+1.99%	-2.29%	-24.04%	+55.15%	-16.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCDA BioCardia	2.8863 of 5 stars	3.8	3.0	1.5	2.5	0.6
BFRI Biofrontera	1.6723 of 5 stars	3.5	3.0	0.6	0.0	0.6
ELAB PMGC	0.2403 of 5 stars	0.0	2.0	1.7	0.0	0.6
IMCC IM Cannabis	0.2508 of 5 stars	0.0	5.0	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	3.50	Strong Buy	$25.00	1,388.10% Upside
BFRI Biofrontera	3.00	Buy	$2.75	189.47% Upside
ELAB PMGC	0.00	N/A	N/A	N/A
IMCC IM Cannabis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELAB, BCDA, BFRI, and IMCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	BFRI Biofrontera	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $2.75

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	154.00	N/A	N/A	$0.18 per share	9.33
BFRI Biofrontera	$38.00M	0.25	N/A	N/A	$0.57 per share	1.67
ELAB PMGC	$1.71M	1.52	N/A	N/A	$11.53 per share	0.16
IMCC IM Cannabis	$54.47M	0.19	N/A	N/A	$1.03 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$7.95M	-$2.33	N/A	N/A	N/A	N/A	-30,792.60%	-223.06%	8/12/2025 (Estimated)
BFRI Biofrontera	-$17.76M	-$2.26	N/A	N/A	N/A	-30.33%	-305.13%	-82.67%	8/13/2025 (Estimated)
ELAB PMGC	-$6.25M	-$433.87	N/A	∞	N/A	N/A	-77.80%	-59.17%	8/13/2025 (Estimated)
IMCC IM Cannabis	-$7.72M	-$0.64	N/A	N/A	N/A	-9.10%	-122.96%	-11.69%	8/12/2025 (Estimated)

Latest ELAB, BCDA, BFRI, and IMCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BFRI Biofrontera	-$0.45	N/A	N/A	N/A	$8.30 million	N/A
5/15/2025	Q1 2025	BFRI Biofrontera	-$0.14	-$0.47	-$0.33	-$0.47	$10.55 million	$8.59 million
5/15/2025	Q1 2025	IMCC IM Cannabis	-$0.2540	$0.06	+$0.3140	$0.06	$11.45 million	$8.69 million
5/14/2025	Q1 2025	BCDA BioCardia	-$0.39	-$0.59	-$0.20	-$0.59	N/A	N/A
5/14/2025	Q1 2025	ELAB PMGC	N/A	-$2.90	N/A	-$2.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
ELAB PMGC	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	0.36	0.36
BFRI Biofrontera	8.99	1.40	0.80
ELAB PMGC	N/A	8.97	8.97
IMCC IM Cannabis	0.10	0.72	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
BFRI Biofrontera	10.08%
ELAB PMGC	22.22%
IMCC IM Cannabis	7.68%

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	20.00%
BFRI Biofrontera	1.20%
ELAB PMGC	0.60%
IMCC IM Cannabis	5.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	40	5.50 million	4.40 million	Optionable
BFRI Biofrontera	70	10.14 million	10.02 million	No Data
ELAB PMGC	18	1.38 million	1.37 million	N/A
IMCC IM Cannabis	340	4.05 million	3.81 million	Not Optionable

ELAB, BCDA, BFRI, and IMCC Headlines

Recent News About These Companies

IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

August 4, 2025 | prnewswire.com

IM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 Million

July 31, 2025 | prnewswire.com

IM CANNABIS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT ON FORM F-3

July 11, 2025 | prnewswire.com

IM Cannabis Announces the Signing of a Loan Agreement and Appointment of Oz Adler to Board of Directors

July 9, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

July 1, 2025 | prnewswire.com

IM Cannabis (NASDAQ:IMCC) Stock, Earnings Estimates, EPS, And Revenue

June 1, 2025 | benzinga.com

IM Cannabis Stock Price, Quotes and Forecasts | NASDAQ:IMCC | Benzinga

June 1, 2025 | benzinga.com

CSE Bulletin: Delist - IM Cannabis Corp. (IMCC)

May 28, 2025 | newsfilecorp.comN

IM Cannabis Corp.: IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

May 28, 2025 | finanznachrichten.de

IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

May 28, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

May 27, 2025 | prnewswire.com

IM Cannabis Corp. (IMCC) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

IM Cannabis Reports First Quarter Financial Results

May 15, 2025 | prnewswire.com

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

May 7, 2025 | prnewswire.com

IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

May 6, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

April 11, 2025 | prnewswire.com

IM Cannabis 2024 net loss ticks up despite successful cost-cutting initiatives

March 31, 2025 | greenmarketreport.comG

IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

March 31, 2025 | prnewswire.com

IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

March 20, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAB, BCDA, BFRI, and IMCC Company Descriptions

BioCardia NASDAQ:BCDA

$1.68 -0.03 (-1.75%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.04 (+2.62%)

As of 04:00 AM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Biofrontera NASDAQ:BFRI

$0.95 -0.07 (-6.86%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$0.94 -0.01 (-1.05%)

As of 08/7/2025 07:50 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

PMGC NASDAQ:ELAB

$1.88 -0.03 (-1.31%)

Closing price 08/7/2025 03:50 PM Eastern

Extended Trading

$1.93 +0.04 (+2.33%)

As of 08/7/2025 07:59 PM Eastern

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

IM Cannabis NASDAQ:IMCC

$2.56 +0.05 (+1.99%)

Closing price 08/7/2025 03:59 PM Eastern

Extended Trading

$2.77 +0.21 (+8.20%)

As of 08/7/2025 07:21 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time